By A. Armstrong
Read or Download Advances in Malignant Melanoma - Clinical, Research Perspectives PDF
Best research books
"Advances in Down Syndrome examine” represents up to date examine in different components of Down Syndrome (DS). a brand new promising animal version of DS is suggested and this opens new possibilities to check pathomechanisms and pharmacological techniques because it is greater than tough to hold out experiences in people and the medical positive factors are hugely variable.
Quantity 39 of "Progress in Drug learn" includes 8 reports and some of the indexes which facilitate its use and determine the con nection with the former volumes. The articles during this quantity take care of polyamines as tumor markers; the histamine (H3)-receptor and its function as a normal regulatory method; with cytokines as immunosti mulants and immunosuppressants in addition to capability anticancer brokers; with fibrinolysis and scientific use of thrombolytic brokers; and with catechol O-methyltransferase and its inhibitors, that are of capability curiosity within the remedy of Parkinson's ailment.
- Qualitative research methods in psychologists : introdution to empirical studies
- Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques
- Insights from Research in Science Teaching and Learning: Selected Papers from the ESERA 2013 Conference
- Nutritional Toxicology. Volume 1
- Project Scheduling: A Research Handbook (International Series in Operations Research & Management Science)
- The Identification of the CF (Cystic Fibrosis) Gene: Recent Progress and New Research Strategies
Additional info for Advances in Malignant Melanoma - Clinical, Research Perspectives
2002). Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanomapancreatic carcinoma-prone families: the familial atypical mole melanomapancreatic carcinoma syndrome. Cancer 94, 84-96. S. (1995). Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 75, 707-714. T. (2007). Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis.
References Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Barnhill R. Sun exposure and mortality from melanoma. JNCI 2005;97:195-199. Bulliard JL, Cox B, Elwood JM. 1994. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control. 5:234-240. Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T. Inhibition of tumor promotion in mouse skin by 1 alpha, 25-dihydroxyvitamin D3. J Cancer Res 1985;45:5426-5430. 36 Advances in Malignant Melanoma – Clinical and Research Perspectives Colston K, Colston MJ, Feldman D.
2008). Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17, 27-36. T. (2000). The FAMMM syndrome: epidemiology and surveillance strategies. Cancer Invest 18, 670-680. F. (2005a). Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41, 45-60. F. (2005b). Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41, 2040-2059.